Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 3Recruiting 2Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 37Melanoma 17Prostatic Neoplasms 16Lung Neoplasms 14Neoplasms 13Squamous Cell Carcinoma of Head and Neck 10Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 9Precancerous Conditions 8Lymphoma 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Leukemia 6Esophageal Neoplasms 6Colorectal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms, Male 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Follicular 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Barrett Esophagus 5Adenocarcinoma Of Esophagus 5Salivary Gland Neoplasms 4Recurrence 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4

Interventions

Carboplatin 49Etoposide 46Cisplatin 42Topotecan 39Irinotecan 21Paclitaxel 20Nivolumab 15pembrolizumab 13Gemcitabine 13atezolizumab 11Ipilimumab 11durvalumab 9Radiotherapy 9Doxorubicin 7Bevacizumab 7rovalpituzumab tesirine 6etoposide phosphate 6amrubicin 6Psychiatric Rehabilitation 6PM 01183 6Docetaxel 6Counseling 6trilaciclib 5Temozolomide 5Sunitinib 5Platinum 5Imatinib Mesylate 5Cyclophosphamide 5Bortezomib 5130-nm albumin-bound paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Carcinoma × Biopsy × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡